Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study

Carmine D’Aniello1, Maria G. Vitale2, Azzurra Farnesi3, Lorenzo Calvetti4, Maria M. Laterza5, Carla Cavaliere6, Chiara Della Pepa7, Vincenza Conteduca8, Anna Crispo9, Ferdinando De Vita5, Francesco Grillone10, Enrico Ricevuto11, Michele De Tursi12, Rocco De Vivo4, Marilena Di Napoli7, Sabrina C. Cecere7, Gelsomina Iovane3, Alfonso Amore13, Raffaele Piscitelli14, Giuseppe Quarto15, Salvatore Pisconti16, Gennaro Ciliberto16, Piera Maiolino14, Paolo Muto17, Sisto Perdonà18, Massimiliano Berretta18, Emanuele Naglieri19, Luca Galli3, Giacomo Carteni2, Ugo De Giorgi8, Sandro Pignata7, Gaetano Facchini7* and Sabrina Rossetti7

Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in second-line treatment of mRCC. The medical records of 62 patients treated with Axitinib, were retrospectively reviewed. The Progression Free Survival (PFS), the Overall Survival (OS), the Objective Response Rate (ORR), the Disease Control Rate (DCR), and the safety profile of axitinib and sunitinib–axitinib sequence, were the primary endpoint. The mPFS was 5.83 months (95% CI 3.93–7.73 months). When compared to patients ≤6 months of prior therapy with Sunitinib (25 and 71%, respectively. When stratified patients by subgroups defined by duration of prior therapy with Sunitinib (< vs. > median duration), there was a statistically significant difference in mPFS with 8.9 (95% CI 4.39–13.40 months) vs. 5.46 months (95% CI 4.04–6.88 months) for patients with a median duration of Sunitinib >13.2 months.
INTRODUCTION

Renal Cell Carcinoma (RCC) accounts for 2–3% of all adult malignancies, representing the seventh most common cancer in men and the ninth most common cancer in women (Escudier et al., 2013). Its incidence has increased over the past several years, contributing to increasing mortality rate. RCC is a family of tumors, each with distinct genetic landscapes, different growth patterns, and metastatic potentials, resulting in a heterogeneous group of disease processes (Linehan et al., 2013). Clear cell renal cell carcinoma (ccRCC) is the most common RCC (75–80% of all primary kidney malignancies; Cohen and McGovern, 2005). Approximately 25–30% of patients with kidney cancer present metastases at the time of diagnosis and ~30% develop recurrent or metastatic disease after radical treatment for localized disease (Leung et al., 2014). Recurrent and/or metastatic renal cell carcinoma (mRCC) is associated with a poor 5-years survival, roughly 10%, however, in the last decade, a series of novel agents have been introduced in clinical practice and the outcomes are slowly improving. Angiogenesis plays a central role in the development, growth, and metastatic progression of RCC via VHL, HIF 1α, VEGF, PDGF, mTOR (PI3K/AKT signaling; Nicol et al., 1997; Dorević et al., 2009; Kornakiewicz et al., 2013; Dimova et al., 2014). Despite an increasing knowledge about the genetic and signaling abnormalities involved in the RCC carcinogenesis, such as VHL, PBRM1, SETD2, and BAP1, no biomarkers are currently available thus there are no molecular factors which may guide the clinicians in choosing the therapeutic strategy (Brugarolas, 2014; D’Aniello et al., 2014; Cavaliere et al., 2015). The advent of the Target Therapies (TTs) has revolutionized the mRCC treatment with an impressive effect on the Overall Survival (OS), which increased from an average of 9 months in 1995, when the only option in first line was interferon-α (IFN-α), to a median of 28–29 months in 2013, the TTs era (Motzer and Russo, 2000; Chowdhury et al., 2008; Albiges et al., 2015; de Velasco et al., 2015). The TTs include the Tyrosine Kinase Inhibitors, TKIs, targeting the Vascular Endothelial Growth Factor Receptors, VEGFRs, the mammalian Target of Rapamycin inhibitors, mTORis, and Bevacizumab, a monoclonal antibody targeting the VEGF ligand.

Axitinib, a potent oral and selective TKi of VEGFR-1, VEGFR-2, and VEGFR-3, has been recently approved in second line after sunitinib or cytokines failure. The second-line phase III AXIS trials compared axitinib, 5 mg twice daily dose-titrated up or down to tolerance, with sorafenib in patients who progressed despite first-line therapy containing sunitinib, bevacizumab plus IFN-α, temsirolimus, or cytokines. The median Progression Free Survival (mPFS), primary endpoint, was 6.7 months with axitinib compared to 4.7 months with sorafenib (HR: 0.665; 95% CI 0.544–0.812; one-sided p < 0.0001) regardless of prior treatment. Partial responses were seen more often after Axitinib than Sorafenib (19.4 vs. 9.4%, p < 0.001). In patients previously treated with Sunitinib, mPFS was 4.8 months in Axitinib arm and 3.4 months in Sorafenib arm (p = 0.011; Rini et al., 2011). In a recent update, the mOS was 20.1 (95% CI 16.7–23.4) with Axitinib and 19.2 months (17.5–22.3) with Sorafenib (HR: 0.969, 95% CI 0.800–1.174; one-sided p = 0.374; Hutson et al., 2013; Motzer et al., 2013). The most common adverse events were diarrhea, hypertension, and fatigue. To date, according to National Cancer Guidelines, Axitinib, Everolimus, and Sorafenib are registered in second-line treatment of mRCC. Evidences from randomized clinical trials, retrospective studies or single-institution experiences do not provide clear and conclusive information which might guide the clinician in choosing Axitinib rather than Everolimus or Sorafenib, or vice versa, in the second-line setting. Hence the decision is made exclusively on the basis of the safety profile and patients medical history. Several “real world” studies have showed the efficacy and safety of Axitinib in unselected populations (Vogl et al., 2013; Basso et al., 2014; Maroto et al., 2014; Matias et al., 2014; Signorovitch et al., 2015; Vogelzang et al., 2015, 2016; Guida et al., 2016; Hutson et al., 2016; Laskey et al., 2016; Pal et al., 2016; Wagstaff et al., 2016), we thought to further reinforce such evidences publishing our own experience with the drug.

PATIENTS AND METHODS

This is a multi-institutional, observational, retrospective study (SAX), which was carried out in nine Italian Oncology Centers, after approval by the National Cancer Institute of Naples Institutional Board. Medical records of patients who were treated with axitinib, in second line, between January 2014 and January 2016 were retrospectively reviewed. All subjects gave written

DCR and ORR to previous Sunitinib treatment was associated with longer statistically mPFS, 7.23 (95% CI 3.95–10.51 months, p = 0.01) and 8.67 (95% CI 4.0–13.33 months, p = 0.008) vs. 2.97 (95% CI 0.65–5.27 months, p = 0.01) and 2.97 months (95% CI 0.66–5.28 months, p = 0.01), respectively. Overall Axitinib at standard schedule of 5 mg bid, was well-tolerated. The most common adverse events of all grades were fatigue (25.6%), hypertension (22.6%), gastro-intestinal disorders (25.9%), and hypothyroidism (16.1%). The sequence Sunitinib–Axitinib was well-tolerated without worsening in side effects, with a median OS of 34.7 months (95% CI 18.4–51.0 months). Our results are consistent with the available literature; this retrospective analysis confirms that Axitinib is effective and safe in routine clinical practice.

Keywords: mRCC, first-line treatment, axitinib, real-life patient, mPFS
informed consent in accordance with the Declaration of Helsinki. To be eligible, patients were required to meet the following inclusion criteria: aged ≥18 years, histologically confirmed RCC, treatment with Axitinib started between January 2014 and January 2016 with at least one radiological reassessment of disease, radiologically measurable disease according to RECIST 1.1 criteria, first line treatment with Sunitinib at least 2 months of therapy. We administered Axitinib according to the conventional and dose-titration schedule.

The primary endpoint was Progression Free Survival, PFS, Overall Survival, OS, Objective Response Rate, ORR, Disease Control Rate, DCR, and the safety profile of Axitinib and Sunitinib–Axitinib sequence. The secondary objectives included the potential relationships between Patient's demographics and baseline characteristics, AEs and response to treatment. PFS was defined as the interval between the date of the first dose of Axitinib and the date of the disease progression or death from any cause; disease progression was defined as radiological tumor progression according to Response Evaluation Criteria In Solid Tumors, RECIST, version 1.1, or clinical progression, including death. AEs were graded according to Common Terminology Criteria for Adverse Events version 4.0.

Descriptive statistics were used to describe Patient's demographics and baseline characteristics, treatment patterns and Adverse Events, AEs. Categorical variables are described by patient counts and percentages. The univariate risks of progression and death were examined: PFS by treatment line of therapy and OS curves were estimated by the Kaplan–Meier and selected variables were compared using two-sided log-rank test. The Cox proportional hazards model was fitted to estimate the risk of progression or of death; hazard ratio (HR) and 95% CI was estimated, adjusted for age, gender, and center. The SPSS statistical package version 23.0 (SPSS Inc., Chicago, IL) was used for all statistical analysis.

RESULTS

Between Jan 2014 and Jan 2016, 62 patients with mRCC or recurrent RCC were eligible for the final analysis.

Patient's demographics and baseline characteristics were summarized in Table 1. Median age was 62 years old, most patients were male (88.7%), the 67.7% had an ECOG Performance Score of 0. Of the 62 patients, 54 (87.1%) had prior nephrectomy and only 4.8% (3/62) had a histological diagnosis different from clear cell. Lung was the first site of metastasis (47.8%) and 6.5% (4/62) of patients had liver metastasis. Based on the MSKCC score classification, only 6.5% (4/62) patients were “poor risk,” the most being “intermediate” 69.4% and “good” 24.2%, while according to Heng score, 12.9% (8/62) patients were “poor risk,” 67.7 and 19.4% were intermediate and favorable risk, respectively.

Clinical Outcomes

The mPFS was 5.83 months (95% CI 3.93–7.73 months; Figure 1). The mOS from the start of Axitinib, was 13.3 months (95% CI 8.6–17.9 months; Figure 2). The ORR, according to RECIST criteria version 1.1 (Eisenhauer et al., 2009) was 25%, with the 23% of patients achieving a Partial Response, PR, and one patient having a Complete Response, CR (Figure 3). The DCR to Axitinib was 71% and correlated with longer statistically mPFS, 9.33 (95% CI 5.51–13.15 months, p < 0.001) vs. 3.26 months (95% CI 2.98–3.54 months, p < 0.001), respectively. DCR and ORR to previous Sunitinib treatment was associated with longer statistically mPFS, 7.23 (95% CI 3.95–10.51 months, p = 0.01) and 8.67 (95% CI 4.0–13.33 months, p = 0.008) vs. 2.97 (95% CI 0.65–5.27 months, p = 0.01) and 2.97 months (95% CI 0.66–5.28 months, p = 0.01), respectively (Table 2). mOS was not reached for ORR (RC), the mean OS according to DCR and ORR was 14.95 (95% CI 12.4–17.49 months, p = 0.056) and 15.66 (95% CI 12.19–19.10 months, p = 0.057) vs. 7.4 (95% CI 3.85–11.0 months, p = 0.056) and 7.42 (95% CI 3.81–11.02 months, p = 0.057), respectively (Table 2). When stratified patients by subgroups defined by duration of prior therapy with Sunitinib (< vs. >median duration), there was a statistically significant difference in mPFS with 8.9 (95% CI 4.39–13.40 months, p = 0.03) vs. 5.46 months (95% CI 4.04–6.88 months, p = 0.03) for patients with a median duration of Sunitinib >13.2 months without differences in mOS (p = 0.27; Table 2). No differences in terms of mPFS according to type of sunitinib-schedule (standard schedule vs. modified

| TABLE 1 | Baseline demographic and clinical patients' characteristics. |
|----------------|-----------------|-----------------|
| Baseline characteristics | N | (%) |
| Median age years (range) | 62 | (36–86) |
| Age | | |
| ≤65 | 39 | (62.9%) |
| >65 | 23 | (37.1%) |
| Gender | | |
| Male | 55 | (88.7%) |
| Female | 7 | (11.3%) |
| ECOG PS | | |
| 0 | 42 | (67.7%) |
| 1 | 18 | (29.0%) |
| 2 | 2 | (3.2%) |
| Prior nephrectomy | | |
| Yes | 54 | (87.1%) |
| No | 8 | (12.9%) |
| MOTZER score | | |
| Poor | 4 | (6.5%) |
| Intermediate | 43 | (69.4%) |
| Favorable | 15 | (24.2%) |
| HENG score | | |
| Poor | 8 | (12.9%) |
| Intermediate | 42 | (67.7%) |
| Favorable | 12 | (19.4%) |
| Site of disease | | |
| Lung | 29 | (47.8%) |
| Bone | 8 | (12.9%) |
| Liver | 4 | (6.5%) |
| Lymph node | 9 | (14.5%) |
| Other | 12 | (19.4%) |
When patients were stratified by Heng score mPFS was 5.73, 5.83, 10.03 months according to poor, intermediate and favorable risk group, respectively. The same results was achieved when used Motzer score, but only Heng score stratification correlated statistically significantly with OS ($p = 0.02$; Table 2). There was no statistically significant difference in mPFS and mOS when stratified patients according to ECOG Performance Status ($p = 0.8$ and 0.7, respectively; Table 2). Prior nephrectomy correlated with longer statistically mPFS ($p = 0.01$) vs. 3.03 months (95% CI 2.86–3.20 months, $p = 0.01$), respectively and also with longer statistically mOS ($p = 0.003$; Table 2), even if the median OS was not reached. Overall Axitinib at standard schedule of 5 mg bid, was well-tolerated, with no grade 4 toxicity. Dose reduction occurred in 21% (13/62) of which five patients in the titration group. The most common adverse events of all grades were fatigue (25.6%), hypertension (22.6%), gastro-intestinal disorders (25.9%), hypothyroidism (16.1%), hand-foot syndrome (8.1%), we observed no cases of dysphonia (Table 3). According to AEs recorded, we did not find predictor of better outcome. The sequence Sunitinib–Axitinib was well-tolerated without worsening in side effects, particularly in terms of hypertension.
D’Aniello et al. Axitinib Real World SAX Study

FIGURE 3 | Kaplan–Meier curve of overall median OS of the patients under study, sunitinib–axitinib sequence.

TABLE 2 | Univariate analysis of mPFS and mOS in our study population.

| p-value | mPFS | mOS |
|---------|------|-----|
| Tumor response rate to prior sunitinib | | |
| DCR | 0.01 | 0.056 |
| ORR | 0.008 | 0.057 |
| Duration of prior sunitinib treatment | | |
| ≤13.2 vs. >13.2 months | 0.03 | 0.27 |
| Heng score | 0.3 | 0.02 |
| ECOG PS | 0.8 | 0.7 |
| Prior nephrectomy | 0.01 | 0.003 |

 Outcome in Dose Titration Axitinib

Dose escalation to 7 or 10 mg bid was feasible in 15 patients (24.2%). mPFS was longer, but not statistically significant, than patients without dose titration, 10.03 (95% CI 2.05–18.015 months, p = 0.07) vs. 5.63 months (95% CI 4.92–6.34 months, p = 0.07), respectively (Table 2). mOS was not significant for dose titration too (p = 0.09, Table 2). Dose titration was well-tolerated with only increase in the incidence of hypothyroidism and fatigue, no worsening of hypertension (Table 3).

DISCUSSION

The development of TTs, VEGFR-TKi, and mTORi, resulted in a significant improvement in terms of both PFS and OS. However, resistance to drugs will occur in most patients. A reasonable approach to overcome drug resistance is the use of sequential therapy, and some drugs that showed efficacy in the second-line setting are in use. The optimization of the disease management should be based on clinical trials but also on real experiences,
Axitinib, a second-generation multi-targeted TKI against VEGFR1, 2 and 3, is licensed in Europe for the treatment of adult patients with mRCC after failure of Sunitinib or cytokines. Efficacy is based on the AXIS trial which reported a longer mPFS in Sunitinib pretreated patients of 6.5 months (95% CI 5.7–7.9 months) with a mOS of 15.2 months (95% CI 12.8–18.3 months). In our analysis, the mPFS was 5.83 months (95% CI 3.93–7.73 months) with a mOS of 13.3 months (95% CI 8.6–17.9 months). These results are similar to the Axis trial and the other real-life experiences (Vogl et al., 2013; Basso et al., 2014; Maroto et al., 2014; Matias et al., 2014; Signorovitch et al., 2015; Vogelzang et al., 2015, 2016; Guida et al., 2015; Hutson et al., 2016; Laskey et al., 2016; Pal et al., 2016; Wagstaff et al., 2016). The majority of the evaluated studies are retrospective analysis of indirect comparison between standard second-line treatments (Everolimus vs. Axitinib) and use Axitinib in second or third line with the median duration of therapy as surrogate of mPFS; others are available only in abstract form, therefore not comparable. Evidences from randomized clinical trials, retrospective studies or single-institution experiences do not provide clear and conclusive information about the optimal sequencing of TTs, furthermore, there is no patients stratification based on prognostic criteria as in first-line. The IMDC model (Heng score) was recently validated in second-line setting resulting more reliable when compared with the three-factor MSKCC model (Heng et al., 2014; Ko et al., 2015). In our retrospective study, when the patients were stratified by Heng score, mPFS was 5.73, 5.83, 10.03 months according to poor, intermediate and favorable risk group, respectively. To date, sequential treatment with VEGF-TKIs or mTORi, represents the standard of care (Chowdhury et al., 2008; Facchini et al., 2009; Calvo et al., 2012; Rizzo et al., 2015; Ko et al., 2015; Linee guida1). The use of EVE is supported by the RECORD-1 trial though the population was not homogeneous for line of treatment (patients who have had two or more prior therapies were also included) and the RECORD-4, a phase II trial, including only patients in the second-line setting, confirmed the efficacy of EVE after SUN or other first-line therapies (Motzer et al., 2008; Motzer R. et al., 2015). The RECORD-4 mPFS was 5.7 months (95% CI 3.7–11.3) with previous Sunitinib, ORR was 7% (95% CI 2–17) and OS 23.8 months (95% CI 13.7–NE; Table 5). The activity of the sequence VEGF-TKI–VEGF-TKI has been demonstrated by several trials showing a longer statistically significant mPFS and in some mOS too (Rini et al., 2011; Motzer et al., 2013; Motzer R. et al., 2015; Hutson et al., 2014; Eichelberg et al., 2015). A network meta-analysis conducted by Leung et al. suggested that axitinib is a more suitable TT option, compared to sorafenib

1Linee guida. Linee guida AIOM. Available online at: www.aiom.it
Our analysis confirm that sequence TKI-TKI therapy with Sunitinib, defined as shorter duration of prior therapy with Sunitinib vs. non-responders. In regards to duration of prior therapy with Sunitinib, defined as shorter (<median) vs. longer (≥median), they detected a significantly longer PFS with second-line Axitinib only in patients who had received a longer prior cytokines treatment (no relationship in patients treated with Sunitinib neither in those who had Sorafenib in second line); OS with second-line Axitinib or Sorafenib was significantly longer in patients who received longer prior therapy, except in those treated with Sunitinib followed by Axitinib (Escudier et al., 2014). On the contrary our analysis showed that, when stratified patients by subgroups defined by duration of prior therapy with Sunitinib (≤ vs. >median duration), there was a statistically significant difference in mPFS with 8.9 (95% CI 4.39–13.40 months, \( p = 0.03 \)) vs. 5.46 months (95% CI 4.04–6.88 months, \( p = 0.03 \)) for patients with a median duration of Sunitinib >13.2 months, without differences in mOS. DCR and ORR to previous Sunitinib treatment was associated with longer statistically mPFS (\( HR = 0.53 \); median PFS (months): 9.4 (5.9–12.2) vs. 3.9 (3.0–5.5), \( p = 0.003 \); TTF(months): 8.0 (5.5–11.0) vs. 3.6 (3.0–4.6), \( p = 0.009 \); Elaidi et al., 2015). Historically, VEGF-targeted therapy was reported to achieve higher ORR (20–30%) compared to mTOR-targeted therapy (≤10%), which is supported by our analysis (Grünwald et al., 2015). The lack of response to a VEGF-targeted agent in the first-line setting does not preclude positive clinical outcomes with a second-line VEGF-targeted agents. Prior nephrectomy correlated with longer statistically mPFS (\( p = 0.01 \)) and mOS (\( p = 0.003 \)). Overall Axitinib at standard schedule of 5 mg bid was well-tolerated, with no grade 4 toxicity. The most common adverse events of all grades were fatigue (25.6%), gastro-intestinal disorders (25.9%), hypertension (22.6%), and hypothyroidism (16.1%). Our data showed a lower incidence of AEs than AXIS trial. According to AEs recorded, we did not find predictor of better outcome, unlike the AXIS analysis showed that patients who developed diastolic blood pressure ≥90 mmHg or systolic below 140 mmHg within the first 8 or 12 weeks of randomization had longer mOS. Dose escalation to 7 or 10 mg bid was feasible in 15 patients (24.2%), without statistically significant differences in terms of both mPFS and OS. Dose titration was well-tolerated with only increase in the incidence of hypothyroidism and fatigue, no worsening of hypertension. It was interesting to note that the 19.3% (12/62) of patients enrolled in our analysis used a modified schedule of Sunitinib (2 w on 1 w off) in first line treatment without differences in terms of outcomes. These results, although on a small size population, confirm those of several retrospective study that evaluated Sunitinib administered on alternative schedules with reduction in the AEs and achieving comparable outcomes to the standard schedule (Atkinson et al., 2014; Bracarda et al., 2015; Lee et al., 2015). Our analysis confirm that sequence TKI-TKI (Sunitinib–Axitinib) was well-tolerated without worsening in side effects, with a mOS for the overall analysis population of 34.7 months (95% CI 18.4–51.0 months), consistent with those of the AXIS trial (33.7 months, 95%CI 28.6–36.96 months). Recently were published the results of CheckMate 025 in which Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with longer mOS, 25.0 months (95% confidence interval [CI], 21.8 to not estimable) vs. 19.6 months (95% CI, 17.6 to 23.1) with everolimus, in previous treated mRCC patients with one or two regimens of anti-angiogenic therapy. It will be interesting to evaluate the efficacy of nivolumab vs. VEGFRI, such as axitinib in second pure line of treatment and their sequencing (Motzer R. J. et al., 2015).

### CONCLUSIONS

Our results are consistent with the available literature; this retrospective analysis confirms the efficacy and safety of Axitinib in an unselected population. DCR, ORR, duration of prior therapy with Sunitinib, and prior nephrectomy may represent prognostic factor of a longer mPFS with Axitinib while only DCR and prior nephrectomy correlated with a longer mOS.
AUTHOR CONTRIBUTIONS
CDA, MV, AF, GF, and SR collected data and wrote the manuscript; AC performed the statistical analysis; LC, ML, CC, CDP, VC, FD, FG, ER, MDT, RD, MDN, SC, GI, AA, RP, GQ, SPisconti, GCiliberto, PMAolin, PMuto, SPerdonà, MB, LG, GGarteni, UD, and S Pignata performed the data collection and the elaboration of data.

REFERENCES
Albiges, L., Choueiri, T., Escudier, B., Galsky, M., George, D., Hofmann, F., et al. (2015). A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur. Urol. 67, 100-110. doi: 10.1016/j.euro.2014.04.006
Atkinson, B. J., Kalra, S., Wang, X., Bathala, T., Corn, P., Tannir, N. M., et al. (2014). Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J. Urol. 191, 611–618. doi: 10.1016/j.juro.2013.08.090
Basso, U., Calvani, N., De Giorgi, U., De Tursi, M., De Vivo, R., Facchini, G., Elaidi, R., Harbaoui, A., Beuselinck, B., Fymard, J.-C., Bamias, A., DeGuillebon, E., et al. (2015). Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Ann. Oncol. 26, 378–385. doi: 10.1093/annonc/mdu552
Escudier, R., Albiges, L., and Songpavde, G. (2013). Optimal management of metastatic renal cell carcinoma: current status. Drugs 73, 427–438. doi: 10.1007/s40265-013-0043-1
Escudier, B., Michaloson, M. D., Motzer, R. J., Hutson, T. E., Clark, J. I., Lim, H. Y., et al. (2014). Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br. J. Cancer 110, 2821–2828. doi: 10.1038/bjc.2014.244
Faccini, G., Perri, F., Caraglia, M., Pisanò, C., Striano, S., Marra, L., et al. (2009). New treatment approaches in renal cell carcinoma. Anticancer Drugs 20, 893–900. doi: 10.1097/CAD.0b013e328331234d
Grünwald, V., McKay, R. R., Krajewski, K. M., Kalanovic, D., Lin, X., Perkins, J. J., et al. (2015). Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur. Urol. 67, 952–958. doi: 10.1016/j.euro.2014.12.036
Guida, A., Albige, L., Loriot, Y., Massard, C., Fizazi, K., and Escudier, B. J. (2016). Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): retrospective experience at Gustave Roussy [Abstract]. J. Clin. Oncol. 34(Suppl. 2S), abstr 527.
Heng, D. Y., Signorovitch, J., Swallow, E., Li, N., Zhong, Y., Qin, P., et al. (2014). Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies. PLoS ONE 9:e114264. doi: 10.1371/journal.pone.0114264
Hutson, T. E., Escudier, B., Esteban, E., Bijnason, G. A., Lim, H. Y., Pittman, K. B., et al. (2014). Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 760–767. doi: 10.1200/JCO.2013.50.3961
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., et al. (2013). Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 14, 1287–1294. doi: 10.1016/S1470-2045(13)70465-0
Hutson, T., Jiao, X., Wilson, T., Cisar, L. A., and MacLean, E. A. (2016). Axitinib treatment among patients with mRCC in a U.S. community oncology setting: a retrospective study of 135 patients [Abstract]. J. Clin. Oncol. 34(Suppl. 2S), abstr 569.
Ko, J. J., Xie, W., Kroeger, N., Lee, J. L., Rini, B. I., Knox, J. J., et al. (2015). The International metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 16, 293–300. doi: 10.1016/S1470-2045(14)72227-7
Kornakiewicz, A., Solarek, W., Bielecka, Z. F., Lian, F., Szczylik, C., and Czarnecka, A. M. (2013). Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma. Curr. Signal Transduct. Ther. 8, 210–218. doi: 10.2174/15734240666614020222746
Laskey, J., Venugopal, B., Thomson, N., O’Donoghue, R., and Jones, R. J. (2016). Axitinib in advanced renal cell carcinoma: outcomes following pazopanib or sunitinib [Abstract]. J. Clin. Oncol. 34(Suppl. 2S), abstr 609.
Lee, J. I., Kim, M. K., Park, I., Ahn, J. H., Lee, D. H., Ryu, H. M., et al. (2015). Randomized phase II trial of Sunitinib four weeks on and two weeks off in metastatic clear-cell type Renal cell carcinoma: RESTORE trial. Ann. Oncol. 26, 2300–2305. doi: 10.1093/annonc/mdv357
Leung, H. W., Chan, A. L., and Lin, S. J. (2014). Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: a network meta-analysis of randomised clinical trials. Mol. Clin. Oncol. 2, 858–864. doi: 10.3892/mco.2014.323
Linehan, W. M., Srinivasan, R., and Garcia, J. A. (2013). Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin. Oncol. 40, 511–520. doi: 10.1053/j.semincancer.2013.05.009
Maroto, P., Lainez, N., Esteban, E., Espinosa, M., Juan, M. J., Etxaniz, O., et al. (2014). Real life efficacy and safety of axitinib (AXI) in patients with renal cell cancer.
D’Aniello et al. Axitinib Real World SAX Study

carcinoma (RCC): results from the Spanish compassionate use program. *Ann. Oncol.* 23(Suppl. 4), iv280–iv304.

Matias, M., Albíges, L., Lassau, N., Benatsou, B., Ablard, C., Massari, F., et al. (2014). Efficacy of axitinib in renal cell carcinoma: real-world experience at Gustave Roussy (IGR) [Abstract]. *J. Clin. Oncol.* 32(Suppl.), abstr e15593.

Motzer, R., Alyasova, A., Ye, D., Karpenko, A., Li, H., Alekseev, B. Y., et al. (2015). RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC) [Abstract]. *J. Clin. Oncol.* 33(Suppl.), abstr 4518.

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., et al. (2015). CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma. *N. Engl. J. Med.* 373, 1803–1813. doi: 10.1056/NEJMoai1510665.

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* 372, 449–456. doi: 10.1016/S0140-6736(08)61039-9.

Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., et al. (2013). Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *Lancet Oncol.* 14, 552–562. doi: 10.1016/S1470-2045(13)70093-7.

Motzer, R. J., and Russo, P. (2000). Systemic therapy for renal cell carcinoma. *J. Urol.* 163, 408–417. doi: 10.1016/S0022-5347(05)67889-5.

Nicol, D., Hii, S. I., Walsh, M., Tch, B., Thompson, L., Kennett, C., et al. (1997). Vascular endothelial growth factor expression is increased in renal cell carcinoma. *J. Urol.* 157, 1482–1486. doi: 10.1016/S0022-5347(01)65028-6.

Pal, S. K., Jonasch, E., Signorovitch, J. E., Reichmann, W. M., Li, N., Liu, Z., et al. (2016). Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. *J. Med. Econ.* 11, 1–7. doi: 10.3111/13696998.2015.1131705.

Rini, B. I., Escudier, B., Tomczak, P., Karprin, A., Szczylik, C., Hutson, T. E., et al. (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet* 378, 1931–1939. doi: 10.1016/S0140-6736(11)61613-9.

Rizzo, M., Facchini, G., Savastano, C., Lorenzoni, G. D., Lucia, L. D., Maiorino, L., et al. (2015). Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study. *Future Oncol.* 11, 219–224. doi: 10.2217/fon.14.170.

Signorovitch, J. E., Kumar Pal, S., Reichmann, W. M., Li, N., Liu, Z., Perez, J. R., et al. (2015). Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: a retrospective chart review [Abstract]. *J. Clin. Oncol.* 33 (Suppl.), abstr e15612.

Vogelzang, N. J., Kumar Pal, S., Signorovitch, J. E., Reichmann, W. M., Chopra, P., Liu, Z., et al. (2015). Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: a retrospective chart review [Abstract]. *J. Clin. Oncol.* 33(Suppl. 7), abstr 500.

Vogelzang, N. J., Pal, S. K., Signorovitch, J. E., Reichmann, W. M., Li, N., Yang, C., et al. (2016). Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. *Curr. Med. Res. Opin.* 32, 741–747. doi: 10.1185/03007995.2016.1140028.

Vogl, U. M., Ponhold, L., Locker, G. L., Zielinski, C., Klingler, C., Kramer, G., et al. (2013). Safety and efficacy of axitinib in pretreated patients with metastatic renal cell carcinoma: a single center experience of the Medical University of Vienna, Austria. *J. Clin. Oncol.* 31(suppl.):abstr e15535.

Wagstaff, J., Jones, R., Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., et al. (2016). Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. *Ann. Oncol.* 27, 159–165. doi: 10.1093/annonc/mdv504.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 D’Aniello, Vitale, Farnesi, Calvetti, Laterza, Cavaliere, Della Pepa, Conteduca, Crispo, De Vita, Grillone, Ricevuto, De Tursi, De Vivo, Di Napoli, Cecere, Iovane, Amore, Piscitelli, Quarto, Pisconti, Facchini and Rossetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.